Immunosupressant organogold compounds

Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional

Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional

InformationBTK inhibitor 1 (Compound 27) BTK inhibitor 1 (compound 27) is an inhibitor of BTK with an IC50 of 0.11 nM for Btk and inhibits B cell activation in hWB with an IC50 of 2 nM.TargetsBTK (Cell-free assay) 0.11 nM.

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.An inhibitor of PDK1,

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.An inhibitor of PDK1,

BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, 140- and 1600-fold more selective for PDK1 than PKA and PKC, respectively. Meanwhile, in comparison to GSK3β more than 100-fold selectivity observed for PDK1.An inhibitor of PDK1,

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK12-IN-3 is a potent and selective CDK12 inhibitor with an IC 50 of 491 nM in enzymatic assay.In VitroCDK12-IN-3 is a highly selective CDK12 inhibitor. CDK12-IN-3 (0.1 μM) shows potent inhibition of phosphorylation of Ser2 on the CTD repeat domain

CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC 50 of 3 nM.In VivoCDK8-IN-1 displays low systemic clearance, very good exposure and oral bioavailability. The t max is 0.25 h by PO. The mean values of C max are 9940 μg/L, 12740 μg/L by